Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castration-Resistant Prostate Cancer (mCRPC)”

422 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 422 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06004661
What this trial is testing

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 23
Not applicableLooking for participantsNCT06600802
What this trial is testing

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

Who this might be right for
Castration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA)
Centre Jean Perrin 120
Not applicableStudy completedNCT03223727
What this trial is testing

Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223

Who this might be right for
Prostate Cancer MetastaticBone Metastases
The Netherlands Cancer Institute 100
Large-scale testing (Phase 3)Ended earlyNCT03850795
What this trial is testing

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer MetastaticCastration-resistant Prostate Cancer
Hinova Pharmaceuticals USA, Inc. 104
Testing effectiveness (Phase 2)Looking for participantsNCT05413850
What this trial is testing

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancermCRPC+3 more
Blue Earth Therapeutics Ltd 82
Early research (Phase 1)Looking for participantsNCT07621692
What this trial is testing

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
National Taiwan University Hospital 12
Testing effectiveness (Phase 2)UnknownNCT04486937
What this trial is testing

SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 90
Large-scale testing (Phase 3)Looking for participantsNCT06855277
What this trial is testing

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 940
Testing effectiveness (Phase 2)Study completedNCT02125357
What this trial is testing

Sequencing Abiraterone and Enzalutamide in mCRPC

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
British Columbia Cancer Agency 202
Large-scale testing (Phase 3)Study completedNCT03016312
What this trial is testing

Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Hoffmann-La Roche 759
Testing effectiveness (Phase 2)Ended earlyNCT03741712
What this trial is testing

SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Who this might be right for
Prostate CancerCastration-resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. 9
Testing effectiveness (Phase 2)Study completedNCT01718353
What this trial is testing

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer Metastatic
Sanofi 63
Testing effectiveness (Phase 2)Study completedNCT02494921
What this trial is testing

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Who this might be right for
Prostate Cancer
Rahul Aggarwal 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT06334432
What this trial is testing

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorHER2-negative Breast CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)+2 more
Nuvation Bio Inc. 466
Early research (Phase 1)Not Yet RecruitingNCT07090369
What this trial is testing

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Peter MacCallum Cancer Centre, Australia 20
Early research (Phase 1)Ended earlyNCT04615845
What this trial is testing

Autologous Dendritic Cell Immunotherapy in Patients With mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Pharmicell Co., Ltd. 3
Testing effectiveness (Phase 2)Looking for participantsNCT07181161
What this trial is testing

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
AstraZeneca 283
Not applicableNot Yet RecruitingNCT07697989
What this trial is testing

Pluvicto Real-world Investigation in Survival in Metastatic CRPC

Who this might be right for
Prostatic Neoplasms, Castration-ResistantNeoplasm Metastasis
Novartis Pharmaceuticals 1,085
Testing effectiveness (Phase 2)Active Not RecruitingNCT04663997
What this trial is testing

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Who this might be right for
Prostate Cancer
Canadian Cancer Trials Group 200
Testing effectiveness (Phase 2)Looking for participantsNCT06615752
What this trial is testing

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Charles Drew University of Medicine and Science 99
Next Page